Sonoma Pharmaceuticals, Inc. Common Stock (SNOA) is a publicly traded Healthcare sector company. As of July 28, 2026, SNOA trades at $1.14 with a market cap of $5.50M and a P/E ratio of -0.60. SNOA moved +0.00% today. Year to date, SNOA is -68.41%; over the trailing twelve months it is -66.37%. Its 52-week range spans $0.85 to $6.92. Rallies surfaces SNOA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Sonoma Pharmaceuticals Q4 Revenue Rises 48% with US Sales Up 194%: Sonoma Pharmaceuticals delivered Q4 revenue of $5.6 million, up 48% year-over-year, with US sales surging 194% to $2.0 million. Net loss narrowed 25% to $0.6 million in Q4 and full-year EBITDA loss improved 38% to $2.1 million, while FY revenue rose 37% to $19.5 million.
| Metric | Value |
|---|---|
| Price | $1.14 |
| Market Cap | $5.50M |
| P/E Ratio | -0.60 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.92 |
| 52-Week Low | $0.85 |
| Volume | 39.98K |
| Avg Volume | 0 |
| Revenue (TTM) | $19.53M |
| Net Income | $-3.17M |
| Gross Margin | 37.97% |
SNOA analyst coverage data. Average price target: $0.00.